Faster Approval Does Not Mean Faster Reimbursement
Several Factors Can Prolong HTA Decision Time
Executive Summary
Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.
You may also be interested in...
France To Speed Up Patient Access To Unapproved Drugs
France's regulatory agency, ANSM, plans to introduce a faster and more equitable system for access to unapproved medicines for individual patients by streamlining its “temporary use authorization” system.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.